Aman U Buzdar researcher
Buzdar, Aman U.
Buzdar, A. U.
Buzdar, Aman U., 19..-....
VIAF ID: 278184528 (Personal)
Permalink: http://viaf.org/viaf/278184528
Preferred Forms
- 100 0 _ ‡a Aman U Buzdar ‡c researcher
- 100 1 _ ‡a Buzdar, A. U.
- 100 1 _ ‡a Buzdar, Aman U
-
-
- 100 1 0 ‡a Buzdar, Aman U.
-
-
-
- 100 1 _ ‡a Buzdar, Aman U., ‡d 19..-....
4xx's: Alternate Name Forms (1)
Works
Title | Sources |
---|---|
Endocrine therapies in breast cancer | |
Fujinka gan | |
Gastrointestinal cancer. | |
Gynecologic cancer. | |
Influence of Comorbidities and Age on Risk of Death Without Recurrence: A Retrospective Analysis of the Arimidex, Tamoxifen Alone or in Combination Trial | |
Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy | |
Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation | |
Locoregional Recurrence Risk for Patients With T1,2 Breast Cancer With 1-3 Positive Lymph Nodes Treated With Mastectomy and Systemic Treatment | |
Locoregional treatment outcomes for inoperable anthracycline-resistant breast cancer. | |
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype | |
Longitudinal nail banding associated with breast carcinoma unrelated to chemotherapy | |
Lorazepam-enhancement of the antiemetic efficacy of dexamethasone and promethazine. A placebo-controlled study | |
Lung cancer. | |
M. D. Anderson cancer care series | |
Mammographic breast density response to aromatase inhibition | |
Management of breast cancer during pregnancy using a standardized protocol | |
Measurement of estrogen and progesterone receptors in human breast tumors: enzyme immunoassay versus binding assay | |
Modifying the Clinical Research Infrastructure at a Dedicated Clinical Trials Unit: Assessment of Trial Development, Activation, and Participant Accrual | |
The natural history of breast carcinoma in patients with > or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study | |
Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer | |
Noninvasive cardiac evaluation of patients receiving adriamycin-containing adjuvant chemotherapy | |
The order of administration of chemotherapy and radiation and its effect on the local control of operable breast cancer | |
Pediatric oncology. | |
A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. | |
The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer | |
The prognostic significance of sialyl-Tn antigen in women treated with breast carcinoma treated with adjuvant chemotherapy | |
Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference | |
The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy | |
Shōni gan | |
Spontaneous regression of breast carcinoma: follow-up report and literature review | |
Su: Cáncer del seno ... | |
Subclinical hepatic toxicity during combination chemotherapy for breast cancer | |
Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma | |
Tamoxifen-induced hypercalcemia in breast cancer | |
Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma | |
Treatment of locoregionally advanced breast cancer with surgery, radiotherapy, and combination chemoimmunotherapy | |
Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience | |
Trends for Inflammatory Breast Cancer: Is Survival Improving? | |
Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer | |
Trioxifene mesylate in the treatment of advanced breast cancer | |
TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression | |
Tumor-associated fever in breast cancer | |
Update on the management of inflammatory breast cancer | |
Use of aromatase inhibitors in postmenopausal women with advanced breast cancer | |
Use of prognostic factors in analysis of historical control studies. | |
Use of tamoxifen for breast cancer: twenty-eight years later | |
Use of Taxol | |
Using response to primary chemotherapy to select postoperative therapy: long-term results from a prospective phase II trial in locally advanced primary breast cancer | |
Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy | |
Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer | |
Vindesine in the treatment of refractory breast cancer: improvement in therapeutic index with continuous 5-day infusion. | |
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks | |
Which threshold for ER positivity? a retrospective study based on 9639 patients | |
Women age < or = 35 years with primary breast carcinoma: disease features at presentation | |
婦人科癌 | |
小児がん | |
消化器癌 | |
転移性乳癌の併用化学療法後に完全寛解した患者の長期的経過観察 |